Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Sumamed; Zithromax; Zithromax IV; Zytromax EV

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PLIVA d.d.
  • Developer Cystic Fibrosis Foundation; Pfizer; St. Michaels Hospital; University of Oxford; University of Wisconsin-Madison
  • Class Antibacterials; Eye disorder therapies; Macrolides; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mycobacterial infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute sinusitis; Bacterial infections; Community-acquired pneumonia; Otitis media; Pelvic inflammatory disorders; Sexually transmitted infections
  • Phase II COVID 2019 infections
  • No development reported Asthma; Cholera; Cystic fibrosis-associated respiratory tract infections; Gastroparesis; Pertussis; Typhoid
  • Discontinued Acute coronary syndromes

Most Recent Events

  • 29 May 2020 Phase-II clinical trials in COVID-2019 infections in United Kingdom (PO) (NCT04381962)
  • 13 May 2020 University of Oxford in collaboration with Pfizer plans a phase II ATOMIC2 trial for COVID-2019 infections, in UK, in May 2020 (NCT04381962) (EudraCT2020-001740-26)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Gastroparesis in Europe (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top